129 related articles for article (PubMed ID: 27582370)
1. Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction.
Beer LA; Kossenkov AV; Liu Q; Luning Prak E; Domchek S; Speicher DW; Ky B
Circ Res; 2016 Oct; 119(10):1135-1144. PubMed ID: 27582370
[TBL] [Abstract][Full Text] [Related]
2. Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer.
Finkelman BS; Putt M; Wang T; Wang L; Narayan H; Domchek S; DeMichele A; Fox K; Matro J; Shah P; Clark A; Bradbury A; Narayan V; Carver JR; Tang WHW; Ky B
J Am Coll Cardiol; 2017 Jul; 70(2):152-162. PubMed ID: 28683962
[TBL] [Abstract][Full Text] [Related]
3. Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer.
Yu AF; Moore ZR; Moskowitz CS; Liu JE; Dang CT; Ramanathan L; Oeffinger KC; Steingart RM; Schmitt AM
JAMA Cardiol; 2023 Jul; 8(7):697-702. PubMed ID: 37256614
[TBL] [Abstract][Full Text] [Related]
4. Left ventricular segmental strain and the prediction of cancer therapy-related cardiac dysfunction.
Demissei BG; Fan Y; Qian Y; Cheng HG; Smith AM; Shimamoto K; Vedage N; Narayan HK; Scherrer-Crosbie M; Davatzikos C; Ky B
Eur Heart J Cardiovasc Imaging; 2021 Mar; 22(4):418-426. PubMed ID: 33206976
[TBL] [Abstract][Full Text] [Related]
5. Variants in structural cardiac genes in patients with cancer therapy-related cardiac dysfunction after anthracycline chemotherapy: a case control study.
Boen HM; Alaerts M; Goovaerts I; Saenen JB; Franssen C; Vorlat A; Vermeulen T; Heidbuchel H; Van Laer L; Loeys B; Van Craenenbroeck EM
Cardiooncology; 2024 Apr; 10(1):26. PubMed ID: 38689299
[TBL] [Abstract][Full Text] [Related]
6. Cardiac dysfunction and their determinants in patients treated for breast cancer and lymphoma: A cardio-oncology center experience.
Khaled S; Abdelkhalek S; Aljuwaybiri R; Almatrafi J; AlHarbi A; Almarhabi R; Alyamani F; Soliman M; Jubran E; Shalaby G
Curr Probl Cardiol; 2024 Jan; 49(1 Pt C):102187. PubMed ID: 37913931
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter.
Dang CT; Yu AF; Jones LW; Liu J; Steingart RM; Argolo DF; Norton L; Hudis CA
J Clin Oncol; 2016 Apr; 34(10):1030-3. PubMed ID: 26834055
[No Abstract] [Full Text] [Related]
8. Nomogram for Predicting Risk of Cancer Therapy-Related Cardiac Dysfunction in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Yu AF; Lin IH; Jorgensen J; Copeland-Halperin R; Feldman S; Ibtida I; Assefa A; Johnson MN; Dang CT; Liu JE; Steingart RM
J Am Heart Assoc; 2023 Oct; 12(19):e029465. PubMed ID: 37750581
[TBL] [Abstract][Full Text] [Related]
9. Activation recovery interval as an electrocardiographic repolarization index to detect doxorubicin-induced cardiotoxicity.
Kinoshita T; Onda N; Ohno R; Ikeda T; Sugizaki Y; Ohara H; Nakagami T; Yuzawa H; Shimada H; Shimizu K; Ikeda T
J Cardiol; 2023 Dec; 82(6):473-480. PubMed ID: 37506822
[TBL] [Abstract][Full Text] [Related]
10. Artificial intelligence-enhanced risk stratification of cancer therapeutics-related cardiac dysfunction using electrocardiographic images.
Oikonomou EK; Sangha V; Dhingra LS; Aminorroaya A; Coppi A; Krumholz HM; Baldassarre LA; Khera R
medRxiv; 2024 Mar; ():. PubMed ID: 38562897
[TBL] [Abstract][Full Text] [Related]
11. Artificial intelligence-enabled prediction of chemotherapy-induced cardiotoxicity from baseline electrocardiograms.
Yagi R; Goto S; Himeno Y; Katsumata Y; Hashimoto M; MacRae CA; Deo RC
Nat Commun; 2024 Mar; 15(1):2536. PubMed ID: 38514629
[TBL] [Abstract][Full Text] [Related]
12. Rationale and Design of the Cessation Of Pharmacotherapy In Recovered Chemotherapy-induced cardioToxicity (COP-RCT): A Pilot Study.
Yu C; Negishi T; Pathan F; Sverdlov A; Thomas L; Shirazi M; Koo CY; Tan LL; Miyazaki S; Negishi K
Heart Lung Circ; 2024 May; 33(5):753-757. PubMed ID: 37949748
[TBL] [Abstract][Full Text] [Related]
13. Risk Profiling of Cancer Treatment-Related Cardiovascular Disorders in Breast Cancer Patients Who Received Adjuvant Chemotherapy With Trastuzumab.
Shinano H; Miyazaki S; Miura K; Ohtsu H; Yonemoto N; Matsuoka K; Konishi H; Daida H; Saito M; Sase K
Circ Rep; 2020 Mar; 2(4):235-242. PubMed ID: 33693235
[No Abstract] [Full Text] [Related]
14. Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores.
Glen C; Adam S; McDowell K; Waterston A; Tan YY; Petrie MC; Coats CJ; Lang NN
JACC CardioOncol; 2023 Oct; 5(5):628-637. PubMed ID: 37969652
[TBL] [Abstract][Full Text] [Related]
15. Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy-Related Cardiac Dysfunction.
Mecinaj A; Gulati G; Ree AH; Gravdehaug B; Røsjø H; Steine K; Wisløff T; Geisler J; Omland T; Heck SL
JACC CardioOncol; 2024 Feb; 6(1):83-95. PubMed ID: 38510299
[TBL] [Abstract][Full Text] [Related]
16. Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study.
Camilli M; Viscovo M; Felici T; Maggio L; Ballacci F; Carella G; Bonanni A; Lamendola P; Tinti L; Di Renzo A; Coarelli G; Galli E; Liuzzo G; Burzotta F; Montone RA; Sorà F; Sica S; Hohaus S; Lanza GA; Crea F; Lombardo A; Minotti G
Cardiooncology; 2024 Mar; 10(1):18. PubMed ID: 38532515
[TBL] [Abstract][Full Text] [Related]
17. New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review.
Alexandraki A; Papageorgiou E; Zacharia M; Keramida K; Papakonstantinou A; Cipolla CM; Tsekoura D; Naka K; Mazzocco K; Mauri D; Tsiknakis M; Manikis GC; Marias K; Marcou Y; Kakouri E; Konstantinou I; Daniel M; Galazi M; Kampouroglou E; Ribnikar D; Brown C; Karanasiou G; Antoniades A; Fotiadis D; Filippatos G; Constantinidou A
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444400
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of surveillance by echocardiography for cancer therapeutics-related cardiac dysfunction of patients with breast cancer.
Okushi Y; Saijo Y; Yamada H; Toba H; Zheng R; Seno H; Takahashi T; Ise T; Yamaguchi K; Yagi S; Soeki T; Wakatsuki T; Sata M; Kusunose K
J Cardiol; 2023 Dec; 82(6):467-472. PubMed ID: 37481235
[TBL] [Abstract][Full Text] [Related]
19. Time course of hypertension and myocardial dysfunction following anthracycline chemotherapy in pediatric patients.
Jacquemyn X; Zhan J; Van den Eynde J; Cordrey K; Long R; Rao S; Barnes BT; Thompson WR; Danford D; Kutty S
Int J Cardiol Heart Vasc; 2024 Aug; 53():101436. PubMed ID: 38872982
[TBL] [Abstract][Full Text] [Related]
20. Genetic predisposition in chemotherapy-induced cardiomyopathy in a 65-year-old female with metastatic breast cancer.
Lee SY; Kim HS; Jung MH; Chang S; Kim M; Youn JC; Chung WB; Jung HO
ESC Heart Fail; 2024 Apr; ():. PubMed ID: 38616291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
